Compare PepsiCo, Inc. (PEP) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs Summit Therapeutics Inc — how do they compare? PepsiCo, Inc. trades at $137.51 (market cap $188.97B), while Summit Therapeutics Inc trades at $17.55 (market cap $13.79B). The key difference: PepsiCo, Inc. is far larger — about 13.7× Summit Therapeutics Inc's market cap, and PepsiCo, Inc. pays a 4.28% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| PEP | SMMT | |
|---|---|---|
Market Cap | $188.97B | $13.79B |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $26.38 |
52-Week Low | $134.95 | $12.43 |
Enterprise Value | $231.47B | $13.11B |
Dividend Yield | 4.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $138.45, up 0.6% with bearish technical signals but strong fundamentals. The company reported consistent earnings beats in recent quarters with Q3 2026 results pending. Revenue grew to $93.93B in 2025, though net income declined to $8.24B. Analysts maintain a consensus price target of $158.79 with 33% buy ratings. Recent news highlights price adjustments on snack products and sponsorship changes.
PEP offers stable dividend income and moderate growth potential, but faces margin pressure from input costs and competitive pricing. The stock trades below analyst targets with solid cash flow generation, though technical indicators suggest near-term weakness. Key risks include consumer sensitivity to price increases and execution challenges in North American markets.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
